Alexandra E Rojek, Justin P Kline, Nicholas Feinberg, Daniel E Appelbaum, Yonglin Pu, Benjamin A Derman, Andrzej Jakubowiak, Satyajit Kosuri, Hongtao Liu, Mariam T Nawas, Sonali M Smith, Michael R Bishop, Peter A Riedell
BACKGROUND: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a standard of care in relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphomas (B-NHL) though the majority of recipients do not receive durable disease benefit, prompting the need to better define risk factors for relapse/progression. OBJECTIVES: We performed a single-center, retrospective analysis of patients treated with commercial CAR T-cell therapy to evaluate the impact of tumor burden, as measured by whole-body metabolic tumor volume (MTV) from 18 F fluorodeoxyglucose PET imaging, on treatment outcomes...
September 16, 2023: Clinical Lymphoma, Myeloma & Leukemia